What Will Happen to Orgenesis Inc. (ORGS) Next? The Stock Just Reaches 52-Week High

March 15, 2018 - By Marguerite Chambers

The stock of Orgenesis Inc. (NASDAQ:ORGS) hit a new 52-week high and has $15.79 target or 6.00 % above today’s $14.90 share price. The 9 months bullish chart indicates low risk for the $153.03 million company. The 1-year high was reported on Mar, 15 by Barchart.com. If the $15.79 price target is reached, the company will be worth $9.18 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 7.24% or $1.0057 during the last trading session, reaching $14.8957. About 325,078 shares traded or 595.19% up from the average. Orgenesis Inc. (NASDAQ:ORGS) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Orgenesis Inc. (NASDAQ:ORGS) to report earnings on May, 23.

More notable recent Orgenesis Inc. (NASDAQ:ORGS) news were published by: Marketwired.com which released: “Orgenesis Acquires Cell Therapy Manufacturer MaSTherCell” on March 09, 2015, also Globenewswire.com with their article: “Orgenesis Completes Reverse Stock Split” published on November 16, 2017, Marketwatch.com published: “Orgenesis Inc.” on June 12, 2017. More interesting news about Orgenesis Inc. (NASDAQ:ORGS) were released by: Globenewswire.com and their article: “Orgenesis Reports 78% Increase in Revenue for the Fourth Quarter of Fiscal 2017” published on March 05, 2018 as well as Marketwired.com‘s news article titled: “Orgenesis and Atvio Biotech Launch Joint Venture for Gene and Cell Therapy …” with publication date: August 01, 2016.

Orgenesis Inc., a biopharmaceutical company, develops trans-differentiation technologies in the field of cell therapy and regenerative medicine. The company has market cap of $153.03 million. The company's Contract Development and Manufacturing Organization segment specializes in cell therapy development for advanced medicinal products. It currently has negative earnings. This segment provides process and assay development services; and GMP contract manufacturing services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.